STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

STORM Therapeutics to present new data on its lead program STC-15 at the 34^th EORTC-NCI-AACR Symposium and the 37^th SITC Meeting

STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3

STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022

20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34^th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37^th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Dr. Jerry McMahon, CEO of STORM Therapeutics commented: “We are delighted to be presenting data from our first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor at these two scientific conferences. These data provide the rationale for the development of STC-15 both as monotherapy and in combination with checkpoint inhibition for the treatment of solid tumour malignancies. STC-15 is on track to enter a Phase 1 First-in-Human clinical study this year and will be the first molecule specifically targeting an RNA methyltransferase to enter clinical development.”

Details of the conferences and presentations are as follow:

34^th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium, 26-28 October, Barcelona, Spain

Session Title: New Therapies in Immuno Oncology

Poster Presentation Title: STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade

Poster Presentation Number: 345

Presenting Authors: Yaara Ofir -Rosenfeld; Oliver Rausch, PhD; Jerry McMahon; Lina Vasiliauskaite; Claire Saunders; Alexandra Sapetschnig; Georgia Tsagkogeorga; Mark Albertella; Marie Carkill; Jezrom Self-Fordham; Josefin-Beate Holz

Date & Time:  Friday 28 October, 10.00 – 15.00 CET

37^th Society for Immunotherapy of Cancer (SITC) Annual Meeting, 10-12 November, Boston, USA

Session Title: Novel Single-Agent Immunotherapies

Poster Presentation Title: STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade

Poster Presentation Number: 1373

Presenting Authors: Joanna Obacz, Yaara Ofir -Rosenfeld; Oliver Rausch, PhD; Jerry McMahon; Lina Vasiliauskaite; Claire Saunders; Alexandra Sapetschnig; Georgia Tsagkogeorga; Mark Albertella; Marie Carkill; Jezrom Self-Fordham; Josefin-Beate Holz

Date & Time: Thursday 10 November, 09:00 – 21.00 EST